Researchers at the Institute of Science Tokyo created an innovative enzyme switch called Switchbody that activates only when bound to its target antigen. The technology uses a trap-and-release mechanism that could revolutionize diagnostics and therapeutics. The team published their findings in Advan
Researchers have developed an AI model that predicts peptide sequences to prevent ribosome stalling in E. coli protein production. This breakthrough could dramatically improve sustainable manufacturing of pharmaceuticals, biofuels, and industrial enzymes. The technology represents a major step forwa
Researchers are reportedly developing synthetic organisms that incorporate non-canonical amino acids into proteins, creating products impossible through conventional methods. The technology leverages ribosomes as high-fidelity engines and eliminates the need for toxic solvents in manufacturing processes.
Sources indicate that synthetic biology company Constructive Bio has developed technology enabling full flexibility in incorporating new chemistries into cellular protein structures. According to reports, their approach harnesses the ribosome as what company CEO Ola Wlodek describes as “this ultimate, high-fidelity engine for making new products.” The method reportedly exploits what analysts suggest is “the ultimate scalability of life” through bacterial cells propagating in bioreactor systems at near room temperature.
Europe’s emerging food biotechnology sector faces regulatory fragmentation and capital bottlenecks despite significant growth potential. A new cross-sector alliance aims to align research, policy and investment to build consumer trust and scale innovation. Industry analysts suggest food biotech could capture a $138 billion global market within the decade.
Europe’s next wave of biotechnology innovation could redefine the continent’s food security as climate disruption and supply-chain pressures intensify, according to industry reports. Despite this potential, sources indicate that food applications have received limited attention in Brussels’ proposed Biotech Act, which aims to harmonize rules and accelerate approvals across sectors.
Circle Pharma will present promising preclinical data on its first-in-class oral macrocyclic cyclin D1-selective inhibitors at the upcoming AACR-NCI-EORTC conference. The company’s innovative approach targets cyclin D1-driven cancers through selective disruption of the cyclin D1-Rb interaction.
Circle Pharma, a clinical-stage biopharmaceutical company focused on developing targeted macrocycle therapeutics, has announced an upcoming poster presentation highlighting the significant anti-tumor potential of cyclin D1 RxL inhibition. The presentation will occur at the prestigious AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston from October 22-26, 2025.
